« Back to Record
Citation APA

Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C. M., Gomez, H., Dinh, P., Fauria, K., van Dooren, V., Aktan, G., Goldhirsch, A., Chang, T.-W., Horváth, Z., Coccia-Portugal, M., Domont, J., Tseng, L.-M., Kunz, G., Sohn, J. H., Semiglazov, V., Lerzo, G., Palacova, M., Probachai, V., Pusztai, L., Untch, M., Gelber, R., Piccart-Gebhart, M., & NeoALTTO Study Team, (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 379(9816), 633-640. doi:10.1016/S0140-6736(11)61847-3


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/144694

Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C. M., Gomez, H., Dinh, P., Fauria, K., van Dooren, V., Aktan, G., Goldhirsch, A., Chang, T.-W., Horváth, Z., Coccia-Portugal, M., Domont, J., Tseng, L.-M., Kunz, G., Sohn, J. H., Semiglazov, V., Lerzo, G., Palacova, M., Probachai, V., Pusztai, L., Untch, M., Gelber, R., Piccart-Gebhart, M., & NeoALTTO Study Team, (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 379(9816), 633-640. doi:10.1016/S0140-6736(11)61847-3